[HTML][HTML] NIR-triggered and ROS-boosted nanoplatform for enhanced chemo/PDT/PTT synergistic therapy of sorafenib in hepatocellular carcinoma
C Wang, X Cheng, H Peng, Y Zhang - Nanoscale Research Letters, 2022 - Springer
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
C Wang, X Cheng, H Peng… - Nanoscale Research …, 2022 - search.proquest.com
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma.
C Wang, X Cheng, H Peng… - Nanoscale Research …, 2022 - search.ebscohost.com
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
C Wang, X Cheng, H Peng… - Nanoscale Research …, 2022 - ui.adsabs.harvard.edu
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma.
C Wang, X Cheng, H Peng, Y Zhang - Nanoscale Research Letters, 2022 - europepmc.org
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
[HTML][HTML] NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
C Wang, X Cheng, H Peng, Y Zhang - Nanoscale Research Letters, 2022 - ncbi.nlm.nih.gov
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma
C Wang, X Cheng, H Peng… - Nanoscale research …, 2022 - pubmed.ncbi.nlm.nih.gov
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma.
C Wang, X Cheng, H Peng, Y Zhang - Nanoscale Research Letters, 2022 - europepmc.org
Although being the first-line treatment of advanced hepatocellular carcinoma (HCC),
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …
sorafenib (SOR) outcome is limited due to drug resistance and low tumor accumulation …